Q-omics provides the consensus-scored WASHC2C profile across patient tissues and cancer cell-line models. WASHC2C expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, WASHC2C is differentially expressed in 11, with the highest sampling consensus in COAD. Additionally, WASHC2C RNA expression shows 19,410 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight LIHC, COAD, and UVM as cancer lineages where WASHC2C shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for WASHC2C — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes WASHC2C survival associations across molecular data types. WASHC2C RNA expression shows survival associations in the most cancer types (24), followed by mutation status (9) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible WASHC2C RNA expression–survival associations across cancer types. High WASHC2C expression shows unfavorable associations in LIHC, KICH, UVM and LUSC, but favorable associations in KIRC and SKCM. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for WASHC2C RNA expression.
This table summarizes WASHC2C tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 6. The strongest signals are observed in COAD for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for WASHC2C. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. WASHC2C shows lower tumor expression in COAD, KICH, LUSC and BRCA and higher tumor expression in LIHC and HNSC. The COAD box plot shows higher WASHC2C RNA expression in normal versus tumor tissue (log2 FC = −1.302, t-test p < 0.001).
This table shows molecular features associated with WASHC2C in patient tissues and cancer cell lines. In patient samples, WASHC2C shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, WASHC2C RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in OVARY and LARGE_INTESTINE.
